MX390100B - Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. - Google Patents
Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.Info
- Publication number
- MX390100B MX390100B MX2017014340A MX2017014340A MX390100B MX 390100 B MX390100 B MX 390100B MX 2017014340 A MX2017014340 A MX 2017014340A MX 2017014340 A MX2017014340 A MX 2017014340A MX 390100 B MX390100 B MX 390100B
- Authority
- MX
- Mexico
- Prior art keywords
- aqueous suspension
- suspension containing
- nanoparticles
- drops
- ear
- Prior art date
Links
- 239000007900 aqueous suspension Substances 0.000 title abstract 5
- 239000003862 glucocorticoid Substances 0.000 title abstract 4
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003221 ear drop Substances 0.000 abstract 2
- 229940047652 ear drops Drugs 0.000 abstract 2
- 239000003889 eye drop Substances 0.000 abstract 2
- 229940012356 eye drops Drugs 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000032625 disorder of ear Diseases 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Un objetivo es proporcionar una suspensión acuosa que contiene como componente activo un compuesto glucocorticosteroide. De modo específico, el objetivo es proporcionar una composición farmacéutica de uso práctico que contiene como componente activo un compuesto glucocorticosteroide. La presente invención es proporcionar una suspensión acuosa que contiene nanopartículas de un compuesto glucocorticosteroide y un estabilizante de dispersión, la suspensión acuosa que contiene las nanopartículas con un diámetro medio de partícula de 300 nm o menos y un diámetro de partícula D90 de 450 nm o menos, composiciones farmacéuticas para administraciones parenterales, inyecciones; gotas para los ojos o gotas para los oídos que contienen la suspensión acuosa, de modo más específico gotas para los ojos para tratar o prevenir enfermedades inflamatorias del ojo o gotas para los oídos para tratar o prevenir enfermedades inflamatorias del oído.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015095610 | 2015-05-08 | ||
| PCT/JP2016/063752 WO2016181935A1 (ja) | 2015-05-08 | 2016-05-09 | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014340A MX2017014340A (es) | 2018-09-21 |
| MX390100B true MX390100B (es) | 2025-03-20 |
Family
ID=57248091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014340A MX390100B (es) | 2015-05-08 | 2016-05-09 | Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10588913B2 (es) |
| EP (1) | EP3295943B1 (es) |
| JP (1) | JP6856525B2 (es) |
| KR (2) | KR102390014B1 (es) |
| CN (1) | CN107613985B (es) |
| AU (1) | AU2016262185B2 (es) |
| CA (1) | CA2985171C (es) |
| ES (1) | ES2937023T3 (es) |
| FI (1) | FI3295943T3 (es) |
| HU (1) | HUE061418T2 (es) |
| IL (1) | IL255452B (es) |
| MX (1) | MX390100B (es) |
| PL (1) | PL3295943T3 (es) |
| PT (1) | PT3295943T (es) |
| RU (1) | RU2747803C2 (es) |
| TW (1) | TWI773641B (es) |
| WO (1) | WO2016181935A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110582264B (zh) * | 2017-03-26 | 2022-11-11 | V·R·斯塔福德 | 眼睑皮肤状况的处理方法 |
| US10857160B2 (en) * | 2017-06-23 | 2020-12-08 | Laboratorios Salvat, S.A. | Oil-in-water nanoemulsion composition of clobetasol |
| EP3691654A4 (en) | 2017-09-25 | 2021-11-24 | Surface Pharmaceuticals, Inc. | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES |
| CA3124945A1 (en) | 2018-12-27 | 2020-07-02 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| WO2020223158A1 (en) | 2019-04-30 | 2020-11-05 | The Medical College Of Wisconsin, Inc. | Trans-tympanic membrane delivery platform and uses thereof |
| LT3769753T (lt) | 2019-07-23 | 2022-05-10 | Nicox Ophthalmics, Inc. | Sterilių oftalmologinių vandeninių flutikazono propionato a formos nanokristalų suspensijų gavimo būdas |
| CN112656760B (zh) * | 2019-09-27 | 2022-04-12 | 武汉科福新药有限责任公司 | 一种二氟泼尼酯混悬滴眼液及其制备方法 |
| JP7641566B2 (ja) * | 2021-04-21 | 2025-03-07 | 学校法人近畿大学 | 超微細化水難溶性薬物及び水溶性薬物を含む点眼剤並びにその製造方法及び使用方法 |
| WO2022240598A1 (en) | 2021-05-10 | 2022-11-17 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| KR102653853B1 (ko) * | 2021-06-21 | 2024-04-01 | 가톨릭대학교 산학협력단 | 약물 전달용 나노서스펜션 및 이의 용도 |
| KR20240086291A (ko) * | 2022-12-09 | 2024-06-18 | 가톨릭대학교 산학협력단 | 약물 전달용 조성물 및 이의 용도 |
| CN116077669B (zh) * | 2022-12-15 | 2024-11-15 | 中南大学湘雅医院 | 用于治疗关节痛的糖皮质激素纳米脂质载体、制法及应用 |
| AU2023446460A1 (en) * | 2023-05-01 | 2025-09-04 | Formosa Pharmaceuticals, Inc. | Method of treating operative complications of cataract surgery |
| AU2024265712A1 (en) * | 2023-05-01 | 2025-11-13 | Aimmax Therapeutics, Inc. | Corticosteroid nanosuspensions and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| ZA966579B (en) | 1995-08-04 | 1998-02-02 | Wakamoto Pharma Co Ltd | O/W emulsion composition for eye drops. |
| ES2284202T3 (es) | 1997-05-14 | 2007-11-01 | Senju Pharmaceutical Co., Ltd. | Preparaciones acuosas en suspension con excelente redispersabilidad. |
| JP4167463B2 (ja) * | 1997-05-14 | 2008-10-15 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
| IT1303692B1 (it) * | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione. |
| US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| EP2283864A1 (en) * | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| WO2008066899A2 (en) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
| TWI405590B (zh) * | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | 微粉碎化有機化合物粒子之製法 |
| MX2010012397A (es) | 2008-05-14 | 2011-03-15 | Otonomy Inc Star | Composiciones de corticosteroides de liberacion controlada y metodos para el tratamiento de transtornos oticos. |
| RU2535017C2 (ru) | 2008-09-19 | 2014-12-10 | Активус Фарма Ко., Лтд. | Композитный порошок из органического вещества для применения в медицине, способ его получения и его суспензия |
| EP2627317A4 (en) | 2010-10-15 | 2014-08-20 | Glaxo Group Ltd | MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE |
| WO2012127037A2 (en) * | 2011-03-24 | 2012-09-27 | Leo Pharma A/S | A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative |
| AU2013259150B2 (en) | 2012-05-11 | 2016-07-14 | Formosa Pharmaceuticals, Inc. | Organic compound nanopowder, production method therefor, and suspension |
| CA3240136A1 (en) | 2012-11-08 | 2014-05-15 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
-
2016
- 2016-05-06 TW TW105114243A patent/TWI773641B/zh active
- 2016-05-09 AU AU2016262185A patent/AU2016262185B2/en active Active
- 2016-05-09 RU RU2017142694A patent/RU2747803C2/ru active
- 2016-05-09 CN CN201680026845.5A patent/CN107613985B/zh active Active
- 2016-05-09 US US15/571,986 patent/US10588913B2/en active Active
- 2016-05-09 JP JP2017517933A patent/JP6856525B2/ja active Active
- 2016-05-09 EP EP16792660.9A patent/EP3295943B1/en active Active
- 2016-05-09 IL IL255452A patent/IL255452B/en unknown
- 2016-05-09 CA CA2985171A patent/CA2985171C/en active Active
- 2016-05-09 ES ES16792660T patent/ES2937023T3/es active Active
- 2016-05-09 WO PCT/JP2016/063752 patent/WO2016181935A1/ja not_active Ceased
- 2016-05-09 KR KR1020217018618A patent/KR102390014B1/ko active Active
- 2016-05-09 KR KR1020177033330A patent/KR102268710B1/ko active Active
- 2016-05-09 HU HUE16792660A patent/HUE061418T2/hu unknown
- 2016-05-09 PL PL16792660.9T patent/PL3295943T3/pl unknown
- 2016-05-09 FI FIEP16792660.9T patent/FI3295943T3/fi active
- 2016-05-09 PT PT167926609T patent/PT3295943T/pt unknown
- 2016-05-09 MX MX2017014340A patent/MX390100B/es unknown
-
2019
- 2019-12-31 US US16/732,173 patent/US11376262B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390100B (es) | Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. | |
| CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
| PE20150997A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas | |
| AU2018260835A1 (en) | Low molecular weight silk compositions and stabilizing silk compostions | |
| CO2017012573A2 (es) | Formación de nanopartículas de ciclosporina a/ciclodextrina | |
| CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
| ECSP19057713A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cáncer | |
| BR112018003110A2 (pt) | nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos | |
| MX386981B (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). | |
| CY1122500T1 (el) | Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων | |
| MX384021B (es) | Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. | |
| BR112017016093A2 (pt) | composição sólida, curativo de ferida, e, método de fabricação de uma composição | |
| MX2016014320A (es) | Composiciones de suspension de liberacion prolongada. | |
| MX2017005904A (es) | Metodos y composiciones relacionadas con nanoportadores sinteticos con rapamicina en un estado estable, super-saturado. | |
| MX2017004600A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| AR091237A1 (es) | Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) | |
| MX2017009037A (es) | Compuestos espiro triciclicos. | |
| BR112016023815A2 (pt) | composições tópicas para o alívio da dor, produção e uso | |
| UY35298A (es) | Formulación en dispersión sólida de un compuesto antiviral | |
| MX2017009699A (es) | Composicion de suspension oftalmica. | |
| MX2019010852A (es) | Nanoparticulas a base de lipidos con estabilidad mejorada. | |
| AR101911A1 (es) | Composiciones de polietileno con propiedades ópticas mejoradas | |
| MX2019009606A (es) | Bis-compuestos para dispositivos opticamente activos. | |
| CL2017000120A1 (es) | Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares | |
| MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. |